PreScience Labs

Progressing to Phase I

PreScience Labs has successfully completed preclinical mechanistic, in–vitro and animal testing using the intro–arterial delivery of it’s proprietary drug 3–bromopyruvate ( “3–BrPA” or “PSL-001” ), The US Food & Drug Administration approved immediate enrollment of a Phase 1, dose–escalating study.

To be alerted to new PSL developments, join our mailing list